Patent Assignment
Reel/Frame 058815/0857
Assignment of Assignor's Interest
Recorded: 2021-11-10
Pages: 13
Assignor
INCYTE CORPORATION
Executed: 2017-01-23
Assignees
INCYTE CORPORATION
1801 AUGUSTINE CUT-OFF, WILMINGTON, DELAWARE, 19803
INCYTE HOLDINGS CORPORATION
1801 AUGUSTINE CUT-OFF, WILIMINGTON, DELAWARE, 19803
Covered Properties
(157)
Bipyrazole Derivatives as Jak Inhibitors
Sustained Release Dosage Forms for a JAK1 Inhibitor
Survival Benefit in Patients with Solid Tumors with Elevated C-Reactive Protein Levels
Application:
14/463,232 →
Publication:
US 2015/0065447
Furo- and Thieno-Pyridine Carboxamide Compounds Useful as Pim Kinase Inhibitors
Bicyclic Heterocycles as Bet Protein Inhibitors
SUBSTITUTED PYRROLO[2,3-c]PYRIDINES AND PYRAZOLO[3,4-c]PYRIDINES AS BET PROTEIN INHIBITORS
Tricyclic Heterocycles as Bet Protein Inhibitors
Cyclopropylamines as LSD1 Inhibitors
Cyclopropylamines as LSD1 Inhibitors
Cyclopropylamines as LSD1 Inhibitors
Cyclopropylamines as LSD1 Inhibitors
JAK1 Inhibitors for the Treatment of Myelodysplastic Syndromes
Application:
14/633,605 →
Publication:
US 2015/0246046
Treatment of B-Cell Malignancies by a Combination Jak and PI3K Inhibitors
1H-Pyrrolo[2,3-C]Pyridin-7(6H)-Ones and Pyrazolo[3,4-C]Pyridin-7(6H)-Ones as Inhibitors of Bet Proteins
Processes of Preparing a JAK1 Inhibitor and New Forms Thereto
Treatment of Chronic Neutrophilic Leukemia (Cnl) and Atypical Chronic Myeloid Leukemia (Acml) by Inhibitors of JAK1
Bicyclic Heteroarylaminoalkyl Phenyl Derivatives as PI3K Inhibitors
SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LSD1 INHIBITORS
SUBSTITUTED TRIAZOLO[1,5-a]PYRIDINES AND TRIAZOLO[1,5-a]PYRAZINES AS LSD1 INHIBITORS
Triazolopyridines and Triazolopyrazines as LSD1 Inhibitors
Substituted Imidazo[1,5-a]Pyridines and Imidazo[1,5-a]Pyrazines as LSD1 Inhibitors
Bicyclic Aromatic Carboxamide Compounds Useful as Pim Kinase Inhibitors
Bicyclic Heteroaromatic Carboxamide Compounds Useful as Pim Kinase Inhibitors
Tricyclic Heterocycles as Bet Protein Inhibitors
Bicyclic Heterocycles as FGFR4 Inhibitors
Application:
14/918,868 →
Publication:
US 2016/0115164
Aza-Heteroaryl Compounds as PI3K-Gamma Inhibitors
Bicyclic Heterocycles as FGFR4 Inhibitors
Bicyclic Heterocycles as FGFR4 Inhibitors
Bicyclic Heterocycles as FGFR4 Inhibitors
Tricyclic Heterocycles as Bet Protein Inhibitors
Salts and Processes of Preparing a PI3K Inhibitor
Heterocyclic Compounds as LSD1 Inhibitors
Bicyclic Heterocycles as Bet Protein Inhibitors
Salts of (S)-7-(1-(9H-Purin-6-Ylamino)Ethyl)-6-(3-Fluorophenyl)-3-Methyl-5H-Thiazolo[3,2-A]Pyrimidin-5-One
Application:
15/150,966 →
Publication:
US 2016/0362424
Crystalline Forms of a PI3K Inhibitor
Process for the Synthesis of a Phosphoinositide 3-Kinase Inhibitor
Heterocyclic Compounds and Uses Thereof
Pyridineamine Compounds Useful as Pim Kinase Inhibitors
SUBSTITUTED PYRROLO[2,3-c]PYRIDINES AND PYRAZOLO[3,4-c]PYRIDINES AS BET PROTEIN INHIBITORS
Bipyrazole Derivatives as Jak Inhibitors
Salts of an LSD1 Inhibitor
Cyclopropylamines as LSD1 Inhibitors
Cyclopropylamines as LSD1 Inhibitors
Pyridineamine Compounds Useful as Pim Kinase Inhibitors
Cyclopropylamines as LSD1 Inhibitors
Tricyclic Heterocycles as Bet Protein Inhibitors
Furo- and Thieno-Pyridine Carboxamide Compounds Useful as Pim Kinase Inhibitors
Bicyclic Heterocycles as FGFR4 Inhibitors
Aza-Heteroaryl Compounds as PI3K-Gamma Inhibitors
Cyclopropylamines as LSD1 Inhibitors
Sustained Release Dosage Forms for a JAK1 Inhibitor
Imidazopyridines and Imidazopyrazines as LSD1 Inhibitors
SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LSD1 INHIBITORS
Substituted [1,2,4]Triazolo[1,5-a]Pyridines and Substituted [1,2,4]Triazolo[1,5-a]Pyrazines as LSD1 Inhibitors
Bicyclic Heterocycles as FGFR4 Inhibitors
Bicyclic Heterocycles as FGFR4 Inhibitors
Application:
15/653,079 →
Publication:
US 2017/0320877
Efficient Sensor Data Delivery
Triazolopyridines and Triazolopyrazines as LSD1 Inhibitors
Tricyclic Heterocycles as Bet Protein Inhibitors
Bicyclic Heterocycles as FGFR4 Inhibitors
Processes of Preparing a JAK1 Inhibitor and New Forms Thereto
Tricyclic Heterocycles as Bet Protein Inhibitors
Bicyclic Heterocycles as FGFR4 Inhibitors
Bipyrazole Derivatives as Jak Inhibitors
Heterocyclic Compounds as LSD1 Inhibitors
1H-Pyrrolo[2,3-C]Pyridin-7(6H)-Ones and Pyrazolo[3,4-C]Pyridin-7(6H)-Ones as Inhibitors of Bet Proteins
Cyclopropylamines as LSD1 Inhibitors
JAK1 Inhibitors for the Treatment of Myelodysplastic Syndromes
Application:
15/980,052 →
Publication:
US 2019/0111058
Crystalline Forms of a PI3K Inhibitor
Bicyclic Heterocycles as FGFR4 Inhibitors
Application:
15/998,869 →
Aza-Heteroaryl Compounds as PI3K-Gamma Inhibitors
Imidazopyridines and Imidazopyrazines as LSD1 Inhibitors
Treatment of B-Cell Malignancies by a Combination Jak and PI3K Inhibitors
Bicyclic Heteroarylaminoalkyl Phenyl Derivatives as PI3K Inhibitors
SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LSD1 INHIBITORS
Triazolopyridines and Triazolopyrazines as LSD1 Inhibitors
Application:
16/144,365 →
Publication:
US 2019/0119272
Triazolopyridines and Triazolopyrazines as LSD1 Inhibitors
Application:
16/173,612 →
Publication:
US 2019/0152976
Cyclopropylamines as LSD1 Inhibitors
Bicyclic Heterocycles as FGFR4 Inhibitors
Tricyclic Heterocycles as Bet Protein Inhibitors
Bicyclic Heterocycles as FGFR4 Inhibitors
Salts of (S)-7-(1-(9H-Purin-6-Ylamino)Ethyl)-6-(3-Fluorophenyl)-3-Methyl-5H-Thiazolo[3,2-A]Pyrimidin-5-One
Application:
16/295,435 →
Publication:
US 2019/0202840
Bicyclic Heterocycles as FGFR4 Inhibitors
Salts of an LSD1 Inhibitor
Salts and Processes of Preparing a PI3K Inhibitor
Bipyrazole Derivatives as Jak Inhibitors
Tricyclic Heterocycles as Bet Protein Inhibitors
Triazolopyridines and Triazolopyrazines as LSD1 Inhibitors
Bicyclic Heteroarylaminoalkyl Phenyl Derivatives as PI3K Inhibitors
1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
Cyclopropylamines as LSD1 Inhibitors
Application:
16/689,444 →
Publication:
US 2020/0181077
Sustained Release Dosage Forms for a JAK1 Inhibitor
Bicyclic Heterocycles as FGFR4 Inhibitors
JAK1 Inhibitors for the Treatment of Myelodysplastic Syndromes
Application:
16/839,972 →
Publication:
US 2021/0069193
Cyclopropylamines as LSD1 Inhibitors
Treatment of B-Cell Malignancies by a Combination Jak and PI3K Inhibitors
Application:
16/872,794 →
Publication:
US 2021/0093638
Cyclopropylamines as LSD1 Inhibitors
Salts of an LSD1 Inhibitor
Bicyclic Heterocycles as FGFR4 Inhibitors
1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
Heterocyclic Compounds as LSD1 Inhibitors
Bipyrazole Derivatives as Jak Inhibitors
Bicyclic Heterocycles as FGFR4 Inhibitors
Sustained Release Dosage Forms for a JAK1 Inhibitor
1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
Salts and Processes of Preparing a PI3K Inhibitor
Bicyclic Heteroarylaminoalkyl Phenyl Derivatives as PI3K Inhibitors
Bipyrazole Derivatives as Jak Inhibitors
Application:
61/824,683 →
Sustained Release Dosage Forms for a JAK1 Inhibitor
Application:
61/863,325 →
Survival Benefit in Patients with Solid Tumors with Elevated C-Reactive Protein Levels
Application:
61/867,982 →
Furo- and Thieno-Pyridine Carboxamide Compounds Useful as Pim Kinase Inhibitors
Application:
61/869,442 →
Bicyclic Heterocycles as Bet Protein Inhibitors
Application:
61/908,954 →
Bicyclic Heterocycles as Bet Protein Inhibitors
Application:
61/908,968 →
Sustained Release Dosage Forms for a JAK1 Inhibitor
Application:
61/913,066 →
Tricyclic Heterocycles as Bet Protein Inhibitors
Application:
61/918,198 →
Cyclopropylamines as LSD1 Inhibitors
Application:
61/939,458 →
Cyclopropylamines as LSD1 Inhibitors
Application:
61/939,488 →
Cyclopropylamines as LSD1 Inhibitors
Application:
61/939,492 →
Cyclopropylamines as LSD1 Inhibitors
Application:
61/939,520 →
JAK1 Inhibitors for the Treatment of Myelodysplastic Syndromes
Application:
61/946,124 →
Treatment of B-Cell Malignancies by a Combination Jak and PI3K Inhibitors
Application:
61/976,815 →
1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
Application:
61/983,289 →
Processes of Preparing a JAK1 Inhibitor and New Forms Thereto
Application:
61/986,738 →
Processes of Preparing a JAK1 Inhibitor and New Forms Thereto
Application:
61/986,789 →
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
Application:
62/005,492 →
Bicyclic Heteroarylaminoalkyl Phenyl Derivatives as PI3K Inhibitors
Application:
62/010,760 →
Imidazopyrazines as LSD1 Inhibitors
Application:
62/022,913 →
Triazolopyridines and Triazolopyrazines as LSD1 Inhibitors
Application:
62/022,929 →
Imidazopyridines and Imidazopyrazines as LSD1 Inhibitors
Application:
62/022,933 →
Triazolopyridines and Triazolopyrazines as LSD1 Inhibitors
Application:
62/022,944 →
Bicyclic Aromatic Carboxamide Compounds Useful as Pim Kinase Inhibitors
Application:
62/024,333 →
Bicyclic Heteroaromatic Carboxamide Compounds Useful as Pim Kinase Inhibitors
Application:
62/024,366 →
Tricyclic Heterocycles as Bet Protein Inhibitors
Application:
62/050,500 →
Cyclopropylamines as LSD1 Inhibitors
Application:
62/061,258 →
Cyclopropylamines as LSD1 Inhibitors
Application:
62/061,268 →
Cyclopropylamines as LSD1 Inhibitors
Application:
62/061,280 →
Cyclopropylamines as LSD1 Inhibitors
Application:
62/061,283 →
Bicyclic Heterocycles as FGFR4 Inhibitors
Application:
62/067,237 →
Aza-Heteroaryl Compounds as PI3K-Gamma Inhibitors
Application:
62/113,995 →
Bicyclic Heteroaromatic Carboxamide Compounds Useful as Pim Kinase Inhibitors
Application:
62/115,842 →
Bicyclic Heterocycles as FGFR4 Inhibitors
Application:
62/118,698 →
Bicyclic Heterocycles as FGFR4 Inhibitors
Application:
62/118,699 →
Bicyclic Heterocycles as FGFR4 Inhibitors
Application:
62/118,704 →
Bicyclic Heterocycles as FGFR4 Inhibitors
Application:
62/118,712 →
Salts and Processes of Preparing a PI3K Inhibitor
Application:
62/121,697 →
Heterocyclic Compounds as LSD1 Inhibitors
Application:
62/142,717 →
Process for the Synthesis of a Phosphoinositide 3-Kinase Inhibitor
Application:
62/159,674 →
Crystalline Forms of a PI3K Inhibitor
Application:
62/159,726 →
Heterocyclic Compounds and Uses Thereof
Application:
62/159,732 →
Salts of (S)-7-(1-(9H-Purin-6-Ylamino)Ethyl)-6-(3-Fluorophenyl)-3-Methyl-5H-Thiazolo[3,2-A]Pyrimidin-5-One
Application:
62/159,760 →
Pyridineamine Compounds Useful as Pim Kinase Inhibitors
Application:
62/168,230 →
Bicyclic Heterocycles as Fgfr Inhibitors
Application:
62/170,936 →
Heterocyclic Compounds as LSD1 Inhibitors
Application:
62/183,906 →
Bicyclic Heterocycles as FGFR4 Inhibitors
Application:
62/192,661 →
Salts of an LSD1 Inhibitor
Application:
62/204,105 →
Heterocyclic Compounds and Uses Thereof
Application:
62/205,513 →
Salts of an LSD1 Inhibitor
Application:
62/326,246 →
Related Assignments
(19)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jan 13, 2015
From: LI, YUN-LONG; ZHUO, JINCONG; QIAN, DING-QUAN; MEI, SONG
To: INCYTE CORPORATION
Reel/Frame 034693/0611 →
Assignment of Assignor's Interest
Jan 16, 2015
From: LI, YUN-LONG; BURNS, DAVID M.; FENG, HAO; HUANG, TAISHENG
To: INCYTE CORPORATION
Reel/Frame 034738/0446 →
Assignment of Assignor's Interest
Jan 28, 2015
From: YELESWARAM, KRISHNASWAMY; PARIKH, BHAVNISH; MODI, DILIP P.; SHETH, TRUPTI
To: INCYTE CORPORATION
Reel/Frame 034830/0076 →
Assignment of Assignor's Interest
Jan 28, 2015
From: YUE, EDDY W.; COMBS, ANDREW P.; BUESKING, ANDREW W.
To: INCYTE CORPORATION
Reel/Frame 034831/0426 →
Assignment of Assignor's Interest
Feb 4, 2015
From: YUE, EDDY W.; COMBS, ANDREW P.; DOUTY, BRENT
To: INCYTE CORPORATION
Reel/Frame 034883/0963 →
Assignment of Assignor's Interest
Feb 19, 2015
From: RODGERS, JAMES D.; SHEPARD, STACEY; WANG, HAISHENG; SHAO, LIXIN
To: INCYTE CORPORATION
Reel/Frame 034981/0415 →
Assignment of Assignor's Interest
Mar 4, 2015
From: SANDOR, VICTOR
To: INCYTE CORPORATION
Reel/Frame 035083/0859 →
Assignment of Assignor's Interest
Apr 1, 2015
From: WU, LIANGXING; COURTER, JOEL R.; HE, CHUNHONG; QIAN, DING-QUAN
To: INCYTE CORPORATION
Reel/Frame 035309/0536 →
Assignment of Assignor's Interest
Apr 1, 2015
From: WU, LIANGXING; COURTER, JOEL R.; HE, CHUNHONG; KONKOL, LEAH C.
To: INCYTE CORPORATION
Reel/Frame 035308/0122 →
Assignment of Assignor's Interest
Apr 1, 2015
From: WU, LIANGXING; COURTER, JOEL R.; HE, CHUNHONG; QIAN, DING-QUAN
To: INCYTE CORPORATION
Reel/Frame 035308/0784 →
Assignment of Assignor's Interest
Apr 1, 2015
From: WU, LIANGXING; HE, CHUNHONG; QIAN, DING-QUAN; SHEN, BO
To: INCYTE CORPORATION
Reel/Frame 035309/0322 →
Assignment of Assignor's Interest
May 14, 2015
From: SCHERLE, PEGGY A.; LIU, XUESONG
To: INCYTE CORPORATION
Reel/Frame 035639/0710 →
Assignment of Assignor's Interest
Jun 3, 2015
From: COMBS, ANDREW P.; MADUSKUIE, THOMAS P., JR; FALAHAPTISHEH, NIKOO
To: INCYTE CORPORATION
Reel/Frame 035776/0071 →
Assignment of Assignor's Interest
Jun 3, 2015
From: VADDI, KRISHNA
To: INCYTE CORPORATION
Reel/Frame 035776/0214 →
Assignment of Assignor's Interest
Jun 19, 2015
From: ZHOU, JIACHENG; LIU, PINGLI; CHEN, SHILI; WU, YONGZHONG
To: INCYTE CORPORATION
Reel/Frame 035948/0070 →
Assignment of Assignor's Interest
Jun 30, 2015
From: LEOPOLD, LANCE HOWARD; ASSAD, ALBERT
To: INCYTE CORPORATION
Reel/Frame 035940/0297 →
Assignment of Assignor's Interest
Jul 21, 2015
From: WU, LIANGXING; COURTER, JOEL R.; HE, CHUNHONG; LI, JINGWEI
To: INCYTE CORPORATION
Reel/Frame 036141/0105 →
Assignment of Assignor's Interest
Sep 16, 2015
From: LI, YUN-LONG; COMBS, ANDREW P.
To: INCYTE CORPORATION
Reel/Frame 036581/0771 →
Corrective Assignment to Correct the Assignor Name Previously Recorded at Reel: 035776 Frame: 0071. Assignor(S) Hereby Confirms the Assignment .
Aug 3, 2016
From: COMBS, ANDREW P.; MADUSKUIE, THOMAS P.; FALAHATPISHEH, NIKOO
To: INCYTE CORPORATION
Reel/Frame 039559/0312 →